Multiple Sclerosis (MS) is the most common chronic neurologic disability in young adult
females in their childbearing ages. Little evidence is available regarding the association
between exposure to IFN-beta (β) products and adverse pregnancy outcomes. Therefore the four
marketing holders of IFN-β are conducting a European-wide IFN-β pregnancy registry.
Additionally, the Committee for Medicinal Products for Human Use (CHMP) has requested a study
to enable identification of pregnancy outcomes in the MS population unexposed to IFN-β
products for comparison with the ongoing European IFN-β Pregnancy Registry.
Details
Lead Sponsor:
Bayer
Collaborators:
Biogen EPID Research Merck Serono Europe Ltd Novartis Pharmaceuticals